Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 2/20 | 0.43 |
| ▸ | SKP1 | P63208 | 2/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192015 | 1.00 | KIT (0.48) | KITCNR1CNR2MAP4K4CKS1B | |
| SCHEMBL17634051 | 0.84 | AKT1 (0.39) | ALDH1A1 | |
| SCHEMBL926142 | 0.84 | AKT1 (0.39) | ALDH1A1 | |
| SCHEMBL28088450 | 0.83 | AKT3 (0.34) | KITCNR1CNR2 | |
| SCHEMBL3663646 | 0.82 | MAPT (0.43) | GPR119ALDH1A1LMNAMAPTOPRD1 | |
| SCHEMBL24085581 | 0.81 | AKT3 (0.56) | KIT | |
| SCHEMBL16616117 | 0.81 | KIT (0.48) | KITCNR1CNR2MAP4K4CKS1B | |
| SCHEMBL22308404 | 0.81 | AKT3 (0.56) | KIT | |
| SCHEMBL30466964 | 0.81 | KIT (0.47) | KITCNR1CNR2MAP4K4CKS1B | |
| SCHEMBL3939523 | 0.81 | AKT1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2025-05-15 | — | — | US | disclosed |
| CN-117677614-A | Heterocyclic compound with AKT kinase inhibition activity, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4282973-A2 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| CN-112062727-B | Process for the preparation of (cyclopenta [ d ] pyrimidin-4-yl) piperazine compounds | 豪夫迈·罗氏有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3656764-B1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023109540-A1 | HETEROCYCLIC COMPOUND WITH AKT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-110590606-B | Process for preparing pyrimidylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3626710-B1 | PROCESS FOR PREPARING AN INTERMEDIATE IN THE SYNTHESIS OF (CYCLOPENTYL[D]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-02-16 | — | — | EP | disclosed |
| CN-105899492-B | Process for preparing pyrimidylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2021-08-24 | — | — | CN | disclosed |
| EP-2170863-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009089453-A9 | HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS AKT PROTEIN KINASE INHIBITOR | ARRAY BIOPHARMA INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009089453-A1 | HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS AKT PROTEIN KINASE INHIBITOR | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| EP-2049500-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049501-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009006567-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006032-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | KIT 2033/4885CNR1 3040/4885CNR2 3060/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | KIT 1474/4885CNR1 2540/4885CNR2 2962/4885 |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | KIT 1474/4885CNR1 2540/4885CNR2 2962/4885 |
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | KIT 1474/4885CNR1 2540/4885CNR2 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.